As the leaves settle on the ground, so do the newest Venture for America fellows into the place they’ll call home for the next two years. The food hall R. House, which was spearheaded by two VFA Fellows, hosted the full group last week, giving new fellows had the chance to mingle and chow down on gourmet hors d’oeuvres with the current cohort and local community of supporters.
What began as a kind of business experiment in innovation has acquired a life of its own.
The idea in 2011 was to create a space at what was then Johnson & Johnson’s pharmaceutical research and development facility in San Diego for an “innovation center,” a place where 18 to 20 life sciences startups could incubate, replete with lab space and equipment. J&J would screen applicants and charge them to lease the space, but would not require an ownership stake or impose licensing requirements on the startups. It would be a “no strings attached” deal.
Infosecurity Group, the founders of Europe’s no.1 information security event, is pleased to announce Inky as the Infosecurity North America Cyber Start-up Company of the Year 2017. Four start-ups competed today during Infosecurity North America 2017 Expo and Conference, presenting their elevator pitches to a judging panel of venture capitalists.
Dreamit has teamed with Accenture, one of the world’s leading professional services companies, to connect Accenture’s strategy and innovation leadership to the startup founders at Dreamit working on transformational products in health tech and urban tech.
This semester, FastForward U (FFU) will begin offering entrepreneurial advising to students looking to start a company or business venture. FFU is an initiative from Johns Hopkins Technology Ventures (JHTV), an office that facilitates licensing and patents for Hopkins researchers and supports technology startups.
The Association of University Research Parks (AURP) today announced the recipients of the Awards of Excellence recognized during its 2017 International Conference hosted by Cummings Research Park in Huntsville, AL. Additionally, AURP announced the results of the election for its 2018 Board of Directors.
Monday, December 11, 2017
Apella, Alexandria Center for Life Science 6:00 – 7:30 PM
Brick by brick, and startup by startup, the New York biotech scene is slowly being built up. More startup incubators are either up, or in development, than ever before. Several pieces necessary to a functional life sciences ecosystem are now in place, and many other milestones will simply take time to develop and succeed. Yet industry and government leaders, investors, and entrepreneurs can’t get complacent—there is much more that New York can do, right now, to gain ground on other hubs and further establish the region as a top center for life science. If the right progress is made, 2018 could be a signature year for the city—or, if progress proves elusive, the momentum could slip away.
The National Institutes of Health and 11 leading biopharmaceutical companies today launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers — standardized biological markers of disease and treatment response — to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the Foundation for the National Institutes of Health (FNIH), with the Food and Drug Administration serving in an advisory role.
When someone’s body parts are donated, it’s a life-or-death race against the clock as hearts, lungs, livers and hands rapidly deteriorate outside the body.
The partnership will see GamaMabs use MedImmune’s proprietary pyrrolobenzodiazepine (PBD) toxin and linker technology in the research and production of the ADC for targeted cancer therapy. GamaMabs will have exclusive rights to use the proprietary PBD technology in this work and MedImmune will receive an upfront payment, development and commercial milestone payments as well as royalties on net sales.
